Press release
Diabetic Nephropathy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Diabetic Nephropathy Treatment Landscape @ Diabetic Nephropathy Pipeline Outlook [https://www.delveinsight.com/sample-request/diabetic-nephropathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Diabetic Nephropathy Pipeline Report
* On 11 August 2025, Novartis Pharmaceuticals announced a AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.
* On 11 August 2025, Inversago Pharma Inc . conducted a study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due to either Type 1 diabetes mellitus or Type 2 diabetes mellitus.
* DelveInsight's Diabetic Nephropathy pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Diabetic Nephropathy treatment.
* The leading Diabetic Nephropathy Companies such as Serodus AS, Curacle, Certa Therapeutics, Cosette Pharmaceuticals, Boehringer Ingelheim, Lewis and Clark Pharmaceuticals, Shanghai Alebund Pharmaceuticals, Celros Biotech, Inversago Pharma Inc., Akebia Therapeutics, Palatin Technologies, Inc, and Chinook Therapeutics and others.
* Promising Diabetic Nephropathy Pipeline Therapies such as BI 685509, BAY94-8862, Telmisartan capsule 40 mg, Finerenone (BAY94-8862), Canagliflozin, Nidufexor, MT-3995, Nidufexor, Repository Corticotropin Injectio, Bindarit and others.
Stay informed about the cutting-edge advancements in Diabetic Nephropathy treatments. Download for updates and be a part of the revolution in Endocrinology and Metabolic Disorders Care @ I Diabetic Nephropathy Clinical Trials Assessment [https://www.delveinsight.com/sample-request/diabetic-nephropathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Diabetic Nephropathy Emerging Drugs Profile
* SER150: Serodus AS
SER150 is an anti-inflammatory compound with a novel mode of action both inhibiting thromboxane synthase as well as blocking the thromboxane (TP) receptor. SER150 is expected to specifically inhibit the inflammatory processes in various segments of the diabetic kidney and reduce the progression of renal impairment whereby the amount of protein excreted in urine will decrease. Treatment with ACE-inhibitor antihypertensives is the golden standard of treatment of diabetic nephropathy but that treatment does not inhibit the fundamental causes of renal damage nor does it cure the disease. Newer antidiabetic drugs have demonstrated a decrease in loss of kidney function over time. Since the inflammation is a progressive process causing loss of the renal function, SER150 could potentially become a very significant combination (add-on) therapy as standard daily treatment in patients with diabetic kidney disease. It is expected that SER150 treatment delays progression or even prevents development of the disease. Consequently, SER150 may have a blockbuster market potential. Currently, the drug is in Phase II/III stage of its development for the treatment of diabetic kidney disease
* CU01: Curacle
CU01 Dimethyl fumarate (DMF) which is being developed by Curacle. CU01 inhibits TGF-/SMAD signaling by activating Nrf2 and has an excellent therapeutic effect in reducing renal fibrosis by suppressing the expression of extracellular matrix. In the previous clinical studies CU01 showed a significant improvement in the amount of change in eGFR from week 6 after administration, and the consistently increasing change in GFR continued until week 12. CU01 group suppressed the progression of diabetic nephropathy by gradually increasing eGFR during the administration period, so it is presumed to have an improvement effect on diabetic nephropathy. In the CU01 group, the ACR value at week 12 compared to the baseline was statistically significantly decreased (p=0.0441). Currently, the drug is in Phase II stage of its development for the treatment of diabetic nephropathy.
* CTA 382: Certa Therapeutics
CTA 382 is a novel small molecule therapy developed by Certa Therapeutics targeting chronic inflammatory and fibrotic diseases. It selectively inhibits the activity of key pro-inflammatory pathways involved in fibrosis and tissue damage. The drug is being investigated for conditions such as idiopathic pulmonary fibrosis (IPF) and chronic kidney disease (CKD) to improve clinical outcomes by reducing fibrosis and inflammation. Currently, the drug is in Preclinical stage of its development for the treatment of diabetic nephropathy.
The Diabetic Nephropathy Pipeline Report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Nephropathy with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Nephropathy Treatment.
* Diabetic Nephropathy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Diabetic Nephropathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Nephropathy market.
Learn more about Diabetic Nephropathy Drugs opportunities in our groundbreaking Diabetic Nephropathy research and development projects @ Diabetic Nephropathy Unmet Needs [https://www.delveinsight.com/sample-request/diabetic-nephropathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Diabetic Nephropathy Companies
Serodus AS, Curacle, Certa Therapeutics, Cosette Pharmaceuticals, Boehringer Ingelheim, Lewis and Clark Pharmaceuticals, Shanghai Alebund Pharmaceuticals, Celros Biotech, Inversago Pharma Inc., Akebia Therapeutics, Palatin Technologies, Inc, and Chinook Therapeutics and others.
Diabetic Nephropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Diabetic Nephropathy Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Diabetic Nephropathy Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Stay informed about how we're transforming the future of Endocrinology and Metabolic Disorders @ Diabetic Nephropathy Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/diabetic-nephropathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Diabetic Nephropathy Pipeline Report
* Coverage- Global
* Diabetic Nephropathy Companies- Serodus AS, Curacle, Certa Therapeutics, Cosette Pharmaceuticals, Boehringer Ingelheim, Lewis and Clark Pharmaceuticals, Shanghai Alebund Pharmaceuticals, Celros Biotech, Inversago Pharma Inc., Akebia Therapeutics, Palatin Technologies, Inc, and Chinook Therapeutics and others.
* Diabetic Nephropathy Pipeline Therapies- BI 685509, BAY94-8862, Telmisartan capsule 40 mg, Finerenone (BAY94-8862), Canagliflozin, Nidufexor, MT-3995, Nidufexor, Repository Corticotropin Injectio, Bindarit and others.
* Diabetic Nephropathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Diabetic Nephropathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Diabetic Nephropathy Pipeline on our website @ Diabetic Nephropathy Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/diabetic-nephropathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Diabetic Nephropathy Overview
* Diabetic Nephropathy Pipeline Therapeutics
* Diabetic Nephropathy Therapeutic Assessment
* Diabetic Nephropathy- DelveInsight's Analytical Perspective
* Late Stage Diabetic Nephropathy Products (Phase III)
* Drug Name: Company Name
* Mid Stage Diabetic Nephropathy Products (Phase II/III)
* SER150: Serodus AS
* Early Stage Diabetic Nephropathy Products (Phase I)
* Drug Name: Company Name
* Preclinical and Discovery Stage PDiabetic Nephropathy roducts
* CTA 382: Certa Therapeutics
* Inactive Products
* Diabetic Nephropathy Companies
* Diabetic Nephropathy Products
* Diabetic Nephropathy Unmet Needs
* Diabetic Nephropathy Market Drivers and Barriers
* Diabetic Nephropathy Future Perspectives and Conclusion
* Diabetic Nephropathy Analyst Views
* 22. Appendixytt9
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=diabetic-nephropathy-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/diabetic-nephropathy-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diabetic Nephropathy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4155036 • Views: …
More Releases from ABNewswire
Hanley Investment Group Arranges Off-Market Sale of Two Multi-Tenant Retail Pad …
PROVO, Utah - Hanley Investment Group Real Estate Advisors, a nationally recognized real estate brokerage and advisory firm specializing in retail property sales, announced today the off-market sale of Bulldog Plaza, which comprises two multi-tenant retail pad buildings totaling 13,620 square feet at a CVS-anchored shopping center in Provo, Utah. The property is located at the high-traffic intersection of Cougar Boulevard and University Avenue, adjacent to Brigham Young University (BYU)…
EliteBuilderRenovation Expands Service Line with ADU and Garage Conversion Solut …
Tampa Bay general contractor EliteBuilderRenovation is now offering accessory dwelling unit (ADU) and garage conversion services to help homeowners in Hillsborough, Pinellas and Pasco counties create additional living space, or additional income source and increase property value.
Tampa, FL - October 30, 2025 - EliteBuilderRenovation, a licensed and insured general contracting firm (License #CGC1537676) serving Hillsborough, Pinellas and Pasco counties, has announced the expansion of its service offerings to include accessory…
Firework Unveils AVA 4.0: The AI FAQ Redefining Product Discovery in the Era of …
Powered by Firework's proprietary AI Product Graph and seamlessly integrated within its Agentic Commerce Platform, AVA 4.0 redefines how consumers discover and engage with products online. By transforming static PDPs into conversational shopping experiences, AVA 4.0 enables brands to deliver agentic, personalized interactions that engage, educate, and convert, with 10x faster response times, up to 13.5% conversion rates.
San Mateo, CA - October 30, 2025 - Firework, the world's leading Agentic…
The Boulder Group Arranges Sale of Net Leased Starbucks Property in Illinois
The Boulder Group, a net leased investment brokerage firm completed the sale of a single tenant Starbucks located at 1051 Route 59 in Antioch, Illinois for $2,460,000.
The 2,540 square-foot building benefits from its position along Illinois Route 59 (11,500 VPD) and proximity to Illinois Route 173 (12,900 VPD). The property is neighbored by several nationally recognized retailers that include Jewel-Osco, Ace Hardware, CVS Pharmacy, PNC Bank, and Advance Auto Parts.…
More Releases for Diabetic
Diabetic Socks Market Dynamics Shaped by Rising Diabetic Population - Persistenc …
The diabetic socks market is gaining significant traction worldwide, driven by the rising prevalence of diabetes and related complications such as diabetic neuropathy and foot ulcers. Designed specifically to cater to the needs of diabetic patients, these socks play a crucial role in foot protection by preventing blistering, reducing moisture accumulation, and providing cushioning to minimize the risk of ulcers. This article delves deeply into the diabetic socks market, exploring…
Leading Element Driving Change in the Diabetic Footwear Market in 2025: Rising D …
Which drivers are expected to have the greatest impact on the over the diabetic footwear market's growth?
The surge in people with diabetes will spur the expansion of the diabetic footwear market in the future. Diabetes, characterised by high blood sugar levels, is a long-term health issue. Diabetic footwear can prevent severe foot-related issues caused by diabetes and offer several advantages such as enhanced blood flow, ample space for the toes,…
Diabetic Food Market
Future Market Insights (FMI) delivers key insights on the global diabetic food market in its latest report titled “Diabetic Food Market: Global Industry Analysis and Opportunity Assessment, 2014 – 2020”. The global diabetic food market is expected to amplify at a CAGR of 5.9% during the forecast period in terms of value due to various factors, regarding which FMI offers fundamental insights in detail in this report.
On the basis of…
Diabetic Food Market
Diabetes refers to a metabolic disease which leads to high blood sugar levels. The main cause behind diabetes is the insufficient insulin or no response in the body cells where the insulin is produced. Diabetic foods are dietary products rich in carbohydrates and sugar content. They help in controlling rising blood glucose. Diabetic food is low in calorie sweeteners and diet beverages. These products are consumed by diabetic patients and…
Demand for Diabetic Socks Due to Rising Prevalence of Diabetic Neuropathy Expect …
According to the latest market report published by Persistence Market Research titled ‘Diabetic Socks Market: Global Industry Analysis 2012-2016 and Forecast 2017-2025,’ the global diabetic socks market is expected to expand at a CAGR of approximately 4.8% during the forecast period 2017-2025.
To know key findings Request Sample Report @: https://www.persistencemarketresearch.com/samples/19282
Global Diabetic Socks Market: Factors Impacting the Market
The primary factors driving the growth of the global diabetic socks market are increasing…
Diabetic Food Market -
In recent times, diabetes has emerged as one of the most challenging health conditions across the world. According to the WHO, a total of 415 million cases of diabetes were reported globally in 2015. The count is rising at an alarming rate and is expected to reach 642 million in the next 25 years. Till now no medication has been found that can completely cure diabetes. It can only be…
